Recent Therapeutic Improvements in Pediatric Oncology: One Fellow Generation (2020–2025)
Authors:
- Diannet Quintero-GarcíaDQDiannet Quintero-García
- Aina SeguíASAina Seguí
- Andrea G. PalauAPAndrea G. Palau
- Alicia PablosAPAlicia Pablos
- Mariona NadalMNMariona Nadal
- Ana I. VegaAVAna I. Vega
- Itziar BuenoIBItziar Bueno
- Miriam Dacil CañadaMCMiriam Dacil Cañada
- Raquel P. SuarezRSRaquel P. Suarez
- María IriondoMIMaría Iriondo
- Martín CuetoMCMartín Cueto
- Maite GorosteguiMGMaite Gorostegui
Open Access
Abstract
Recent therapeutic advances have significantly transformed the management of selected pediatric malignancies. We conducted a narrative review of recently approved therapies with demonstrated clinical impact in pediatric oncology. Evidence from pivotal clinical trials was integrated with real-world experience at the Pediatric Cancer Center Barcelona (PCCB). Fifty-three new oncological drugs with pediatric indication were available in 2025 that were not in routine clinical practice in 2020. We reviewed 18, those available at the PCCB, to demonstrate their meaningful clinical activity, the improved disease control and favorable toxicity profiles. Overall, 688 patients have benefited from these new agents. Real-world experience supports their feasibility and clinical benefit in many pediatric cancers. We realized that a significant number of novel therapies have been approved in the last 5 years and represent an important step toward precision oncology in pediatric cancer. Their integration into clinical practice is reshaping treatment paradigms and offering real opportunities for patients with otherwise limited options. Ongoing studies will define their long-term impact, optimal sequencing, and role within multimodal treatment strategies.Keywords
This publication has 167 references indexed in Scilit:
- Scaling‐Up Research in Childhood Cancer in Low‐ and Middle‐Income CountriesPediatric Blood & Cancer, 2026
- Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2024
- Current Management of Desmoid TumorsJAMA Oncology, 2024
- FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphomaPediatric Blood & Cancer, 2022
- Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B‐cell acute lymphoblastic leukemiaPediatric Blood & Cancer, 2021
- Naxitamab combined with granulocyte‐macrophage colony‐stimulating factor as consolidation for high‐risk neuroblastoma patients in complete remissionPediatric Blood & Cancer, 2021
- Safety and efficacy of gamma‐secretase inhibitor nirogacestat (PF‐03084014) in desmoid tumor: Report of four pediatric/young adult casesPediatric Blood & Cancer, 2020
- A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastomaInternational Journal of Cancer, 2020
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell HistiocytosisJAMA Oncology, 2018
- Crizotinib in ALK+ inflammatory myofibroblastic tumors—Current experience and future perspectivesPediatric Blood & Cancer, 2017